Literature DB >> 32251632

High ErbB3 activating activity in human blood is not due to circulating neuregulin-1 beta.

Emmanuel Boateng1, Joanne T deKay2, Sarah M Peterson3, Jacob Boles4, Nathan Pinnette5, Mary W Sorcher6, Michael P Robich7, Douglas B Sawyer7, Sergey Ryzhov8.   

Abstract

Neuregulin-1β (NRG-1) is a membrane-bound or secreted growth and differentiation factor that mediates its action by binding to ErbB receptors. Circulating levels of NRG-1 are characterized by large inter-individual variability with the range of absolute values covering two orders of magnitude, from hundreds to tens of thousands of picograms per milliliter of blood. NRG-1 signaling via ErbB receptors contributes to the cell survival and downregulation of the inflammatory response. A higher level of circulating NRG-1 may indicate increased shedding of membrane-bound NRG-1, which in turn can contribute to better protection against cardiovascular stress or injury. However, it is unknown whether circulating NRG-1 can induce activation of ErbB receptors. In the current study, we performed an analysis of circulating NRG-1 functional activity using a cell-based ELISA measuring phosphorylation of ErbB3 induced by blood plasma obtained from healthy donors. We found high levels of ErbB3 activating activity in human plasma. No correlations were found between the levels of circulating NRG-1 and plasma ErbB3 activating activity. To determine the direct effect of circulating NRG-1, we incubated plasma with neutralizing antibody, which prevented the stimulatory effect of recombinant NRG-1 on activation of ErbB3. No effect of the neutralizing antibody was found on plasma-induced phosphorylation of ErbB3. We also found that a significant portion of circulating NRG-1 is comprised of full-length NRG-1 associated with large extracellular vesicles. Our results demonstrate that circulating NRG-1 does not contribute to plasma-induced ErbB3 activating activity and emphasizes the importance of functional testing of NRG-1 proteins in biological samples.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Circulation; ErbB receptors; Extracellular vesicles; NRG-1 neutralizing antibody; Neuregulin-1

Mesh:

Substances:

Year:  2020        PMID: 32251632      PMCID: PMC7233313          DOI: 10.1016/j.lfs.2020.117634

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  66 in total

Review 1.  G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs?

Authors:  Krishna Sriram; Paul A Insel
Journal:  Mol Pharmacol       Date:  2018-01-03       Impact factor: 4.436

2.  ErbB2 promotes endothelial phenotype of human left ventricular epicardial highly proliferative cells (eHiPC).

Authors:  Sergey Ryzhov; Michael P Robich; Daniel J Roberts; Amanda J Favreau-Lessard; Sarah M Peterson; Edward Jachimowicz; Rutwik Rath; Calvin P H Vary; Reed Quinn; Robert S Kramer; Douglas B Sawyer
Journal:  J Mol Cell Cardiol       Date:  2017-12-29       Impact factor: 5.000

3.  Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.

Authors:  Douglas B Sawyer; Christian Zuppinger; Thomas A Miller; Hans M Eppenberger; Thomas M Suter
Journal:  Circulation       Date:  2002-04-02       Impact factor: 29.690

4.  Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells.

Authors:  Yun Jung Park; Hansoo Lee; Jeong-Hyung Lee
Journal:  BMB Rep       Date:  2010-02       Impact factor: 4.778

5.  A single ligand is sufficient to activate EGFR dimers.

Authors:  Ping Liu; Thomas E Cleveland; Samuel Bouyain; Patrick O Byrne; Patti A Longo; Daniel J Leahy
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-14       Impact factor: 11.205

6.  c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential.

Authors:  Richard Marcotte; Lixin Zhou; Harold Kim; Calvin D Roskelly; William J Muller
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

7.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy.

Authors:  Cemil Ozcelik; Bettina Erdmann; Bernhard Pilz; Nina Wettschureck; Stefan Britsch; Norbert Hübner; Kenneth R Chien; Carmen Birchmeier; Alistair N Garratt
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-18       Impact factor: 11.205

8.  ERBB signaling attenuates proinflammatory activation of nonclassical monocytes.

Authors:  Sergey Ryzhov; Anton Matafonov; Cristi L Galindo; Qinkun Zhang; Truc-Linh Tran; Daniel J Lenihan; Carrie Geisberg Lenneman; Igor Feoktistov; Douglas B Sawyer
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-02-24       Impact factor: 4.733

9.  p38 mitogen-activated protein kinase-dependent transactivation of ErbB receptor family: a novel common mechanism for stress-induced IRS-1 serine phosphorylation and insulin resistance.

Authors:  Rina Hemi; Yafit Yochananov; Ehud Barhod; Michal Kasher-Meron; Avraham Karasik; Amir Tirosh; Hannah Kanety
Journal:  Diabetes       Date:  2011-03-08       Impact factor: 9.461

10.  Circulating Microparticles Alter Formation, Structure, and Properties of Fibrin Clots.

Authors:  Laily D Zubairova; Roza M Nabiullina; Chandrasekaran Nagaswami; Yuriy F Zuev; Ilshat G Mustafin; Rustem I Litvinov; John W Weisel
Journal:  Sci Rep       Date:  2015-12-04       Impact factor: 4.379

View more
  1 in total

Review 1.  Neuregulins: protective and reparative growth factors in multiple forms of cardiovascular disease.

Authors:  Andrew Geissler; Sergey Ryzhov; Douglas B Sawyer
Journal:  Clin Sci (Lond)       Date:  2020-10-16       Impact factor: 6.876

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.